CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...
NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...
Zacks Investment Research on MSN
CHMP backs EU approval of MRNA's new COVID-19 vaccine mNexSpike
Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the EU approval of mNexspike ...
From COVID-19 to the seasonal flu and RSV, vaccinations for respiratory viruses are typically delivered via intramuscular injection, which generates antibodies in the bloodstream. But the first line ...
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Moderna, Inc. is placed among them. Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, ...
The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader ...
Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback